Pathway Genomics had a busy week. The San Diego, CA-based genetic testing laboratory began by securing an investment from IBM that will also give it access to Watson, before going on to form a cancer research collaboration with a registry created by researchers from Memorial Sloan Kettering, Mayo Clinic, Dana-Farber and other organizations.
IBM has made another foray into healthcare research. The latest collaboration sees the tech veteran team up with Cleveland Clinic to use Watson in genomics cancer research.
AirStrip and IBM have partnered to create a mobile monitoring solution to aid physicians in tracking and predicting the status of patients with acute and critical illnesses.
Mayo Clinic and IBM have teamed up to apply cutting-edge technology to the age-old problem of enrolling patients into clinical trials. Starting next year Mayo Clinic will use IBM's supercomputer Watson to automatically match patients to clinical trials.
IBM has opened up its Watson supercomputer to drug researchers through a new cloud-based service. And Big Pharma companies are already on board, with Johnson & Johnson and Sanofi among the early adopters of the technology.
PGC set up the bioinformatics center to complement its existing next-generation sequencing work.
When IBM was preparing its artificial-intelligence program Watson to compete on the game show "Jeopardy!," it made the system read Wikipedia. The training worked and Watson beat its human competitors. Now IBM and the New York Genome Center are testing whether making Watson read PubMed can help defeat cancer.
A team from IBM Research and the Institute of Bioengineering and Nanotechnology in Singapore have designed a Vitamin E-based hydrogel that can release Roche's cancer antibody Herceptin under the skin for several weeks.
Having updated its disease-modeling platform last week, tech giant IBM has now snagged a grant to dig into electronic health records to predict heart disease and opened a Big Data research lab.
Belgian biopharma group UCB has partnered with IBM to provide physicians with a predictive tool for use in treating epileptic patients, and the company has worked on expanding its offerings after patents expired on its epilepsy drug Keppra.